

CURRICULUM VITAE

CHIUMENTE MARCO

Data di nascita: 05-05-1984

E- mail: marco.chiumente@sifact.it

<https://orcid.org/0000-0002-0943-6746>



ESPERIENZE PROFESSIONALI

- Da Marzo 2015 ad oggi: **Coordinatore scientifico nazionale SIFaCT**
Coordinamento di progetti di ricerca e formazione professionale su temi di farmacia clinica e ricerca nel settore sanitario
SIFaCT – Società Italiana di Farmacia Clinica e Terapia. Milano
- Giugno 2011 –
Maggio 2015: **Specializzando in *Farmacia Ospedaliera***
A.O. “Città della salute e della scienza di Torino” (Molinette).
ASLTO3 “Ospedale degli infermi di Rivoli” Rivoli (To)
Indirizzo: Farmacia clinica
- Dicembre-Maggio 2011: **Tirocinio volontario**
A.O.U. Molinette
- Luglio-Dicembre 2010: **Farmacista**
Casa di cura – poliambulatorio “Villa Iris”

ISTRUZIONE E FORMAZIONE

- Marzo - Luglio 2014: **Corso di perfezionamento: farmacista di dipartimento**
Università degli studi di Torino
Indirizzo: Farmacia clinica
- Giugno 2011 –
Maggio 2015: **Specializzazione in *farmacia ospedaliera***
Università degli studi di Torino
Indirizzo: Farmacia clinica
Titolo della tesi: Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.
- Giugno 2010: **Abilitazione alla professione di *farmacista***
Ordine dei farmacisti di Torino
- Maggio 2010: **Laurea magistrale a ciclo unico in *Farmacia***
Università degli studi di Torino
Titolo della Tesi: “Ruolo dei canali del Ca²⁺ di tipo L nel controllo dell’attività elettrica e della proliferazione in cellule di insulinoma.

- Marzo 2007: **Laurea Di Primo Livello in *Informazione scientifica sul farmaco*** Università degli studi di Torino
Titolo della Tesi: "Dolore fisiologico e neuropatico: eziologia, fisiopatologia e trattamento farmacologico."
- Luglio 2003: **Diploma di *tecnico di laboratorio chimico-biologico***
ITAS, "Santorre di Santarosa" di Torino

ESPERIENZE INTERNAZIONALI

Duquesne university, Pittsburgh (PA) USA; Washington DC, HTAi congress, Mount Holyoke college, South Hadley, MA; Giugno-Luglio 2014.

Obiettivo di questo soggiorno è stata la creazione di un gruppo interdisciplinare di lavoro e l'implementazione dei progetti inerenti i settori dell'HTA e della farmacia clinica.

Duquesne university, Pittsburgh (PA) USA; Giugno-Luglio 2013.

Durante il soggiorno negli Usa ho approfondito la figura del farmacista territoriale, ospedaliero e clinico negli USA. Dopo aver trascorso un primo periodo di introduzione al sistema americano in tema di educazione universitaria e sistema sanitario ho affiancato i farmacisti clinici impiegati in vari ospedali specializzati in Pennsylvania e stati confinanti (Ohio, West Virginia).

PUBBLICAZIONI

Coautore nei seguenti original article (aggiornamento aprile 2022):

- 1. Disposal practices for unused and expired medications: pilot data from three cities in three countries.**
KM. Kamal, M. Chiumente, S. Nakagawa V. Giannetti, T. Marlin
GMS Health Innov Technol. 2022 Mar 7;16:Doc01. doi: 10.3205/hta000133.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 2. Medical Therapy, Radiofrequency Ablation, or Cryoballoon Ablation as First-Line Treatment for Paroxysmal Atrial Fibrillation: Interpreting Efficacy Through the Shiny Method**
S Trippoli,, L Di Spazio, M. Chiumente, A. Messori
Cureus. 2022 Feb 27;14(2):e22645. doi: 10.7759/cureus.22645.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 3. Age-Adjusted Survival Extrapolations-Results May Differ From Those Generated by the Weibull Model.**
A. Messori, D. Mengato, M. Chiumente
JAMA Cardiol. 2022 Mar 2. doi: 10.1001/jamacardio.2021.6029.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 4. Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is Small.**
D. Mengato, M. Chiumente, A. Messori
J Gastrointest Cancer. 2022 Jan 17. doi: 10.1007/s12029-022-00804-4.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 5. The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune**

Checkpoint Inhibitors.

L. Di Spazio, M. Rivano, L. Cancanelli, M. Chiumente, D. Mengato, A. Messori
Cureus. 2022 Jan 9;14(1):e21065. doi: 10.7759/cureus.21065.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

6. A preliminary estimate of survival gain and cost-effectiveness of CAR-T in adult patients with acute lymphoblastic leukemia.

A. Messori A, M. Rivano, D. Mengato, L. Cancanelli, L. Di Spazio, M. Chiumente
Leuk Lymphoma. 2021 Dec 31:1-4. doi: 10.1080/10428194.2021.2022141.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

7. Efficacy of Immune Checkpoint Inhibitors in Patients with Mismatch Repair-Deficient or Microsatellite Instability-High Metastatic Colorectal Cancer: Analysis of Three Phase-II Trials.
Cureus. 2021 Nov 25;13(11):e19893. doi: 10.7759/cureus.19893.

L. Cancanelli, M. Rivano, L. Di Spazio, M. Chiumente, D. Mengato, A. Messori
Cureus. 2021 Nov 25;13(11):e19893. doi: 10.7759/cureus.19893.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

8. The QOSMOS Study: Pharmacist-Led Multicentered Observational Study on Quality of Life in Multiple Sclerosis.

V. Damuzzo, L. Agnoletto, R. Rampazzo, F. Cammalleri, L. Cancanelli, M. Chiumente, S. Costantino, S. Michielan, F. Milani, A. Sartori, M. Rivano, D. Mengato.

Neurol Int. 2021 Dec 3;13(4):682-694. doi: 10.3390/neurolint13040065.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

9. Oncostability: stability of reconstituted and diluted anticancer medicines for a possible extension of use.

M. Chiumente, M. Rivano, D. Severino, S. Bertoli, AR Gasbarro, R. Santeramo, A. Pasqualini, R. Provasi, D. Mengato, A.C. Palozzo

Eur J Hosp Pharm. 2021 Dec 15:ejhpharm-2021-003157. doi: 10.1136/ejhpharm-2021-003157.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

10. Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy.

L. Cancanelli, D. Mengato, L. Di Spazio, M. Rivano, M. Chiumente, A. Messori Int J Clin Pharmacol Ther. 2022 Jan;60(1):32-35. doi: 10.5414/CP204113.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

11. Hospital Pharmacy Response to Covid-19 Pandemic in Italy: What We Learned From the First Outbreak Wave.

V. Damuzzo, R. Bertin, D. Mengato, M. Chiumente, M. Rivano, AC Palozzo

J Pharm Pract. 2021 Jun 15:8971900211023643. doi: 10.1177/08971900211023643.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

12. Experience in managing independent clinical research, the best training strategy for future clinical pharmacists: the QOSMOS project.

Damuzzo V, Agnoletto L, Rampazzo R, Cammalleri F, Cancanelli L, Chiumente M, Costantino S, Michielan S, Milani F, Sartori A, Mengato D.

Eur J Hosp Pharm. 2021 Jun 24:ejhpharm-2021-002839. doi: 10.1136/ejhpharm-2021-002839.

[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

13. COVID-19 impact on skills and professional perceptions of the hospital pharmacist during the first outbreak wave.

Damuzzo V, Bertin R, Mengato D, Chiumente M, Rivano M, Palozzo AC.

JPP. 2021 Apr 13:ejhpharm-2021-002765. doi: 10.1136/ejhpharm-2021-002765. Online ahead of print. [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

14. Preparation of intravenous chemotherapy bags: evaluation of a dose banding approach in an Italian oncology hospital.

Chiumente M, Russi A, Todino F, Mengato D, Coppola M, Rivano M, Palozzo A, Jommi C. GRHTA [Internet]. 26Mar.2021 [cited 1Jun.2021];8:29

[EMBASE and GOOGLE SCHOLAR INDEXED]

15. **Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors.**
Di Spazio L, Cancanelli L, Rivano M, Chiumente M, Mengato D, Messori A.
Eur Rev Med Pharmacol Sci. 2021 Feb;25(4):1881-1889. doi: 10.26355/eurrev_202102_25083.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
16. **SARS-COV-2 pandemic: establishing three risk levels for 19 Italian regions and two autonomous provinces.**
Messori A, Angileri M, Chiumente M, Agnoletto L, Baldo P, Bartoli L, Cirino M, Damuzzo V, Ferracane E, Giron MC, Laudisio C, Mengato D, Palozzo AC, Trippoli S.
Eur J Hosp Pharm. 2021 Feb 8;ejhpharm-2021-002692. doi: 10.1136/ejhpharm-2021-002692.
Online ahead of print. [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
17. **The Restricted Mean Survival Time as a Tool for Ranking Comparative Outcomes in a Narrative Review that Evaluates a Network of Randomized Trials: An Example Based on PCSK9 Inhibitors.**
Messori A, Bartoli L, Chiumente M, Mengato D, Trippoli S. Am J Cardiovasc Drugs. 2021 May;21(3):349-354. doi: 10.1007/s40256-020-00444-8.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
18. **Toward a common understanding of competencies for health technology assessment: enhancing educational and training programs around the globe.**
Mueller D, Gutierrez-Ibarluzea I, Chiumente M, Oortwijn W.
Int J Technol Assess Health Care. 2020 Dec 7;37:e29. doi: 10.1017/S0266462320001919.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
19. **Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.**
Messori A, Bartoli L, Mengato D, Chiumente M.
Eur J Hosp Pharm. 2020 Nov 30;ejhpharm-2020-002609. doi: 10.1136/ejhpharm-2020-002609.
Online ahead of print.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
20. **Restricted mean survival time as outcome measure in advanced urothelial bladder cancer: analysis of 4 clinical studies.**
Rivano M, Cancanelli L, Spazio LD, Chiumente M, Mengato D, Messori A.
Immunotherapy. 2021 Feb;13(2):95-101. doi: 10.2217/imt-2020-0160.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
21. **OMEGA-3 for the prevention of cardiovascular diseases: meta-analysis and trial-sequential analysis**
Cabiddu MF, Russi A, Appolloni L, Mengato D, Chiumente M.
Eur J Hosp Pharm. 2020 Jun 16;ejhpharm-2020-002207. doi: 10.1136/ejhpharm-2020-002207.
Online ahead of print. [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
22. **Axicabtagene ciloleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median**
Messori A, Chiumente M, Mengato Ther Adv Med Oncol. 2020 Jun 3;12:1758835920930643. doi: 10.1177/1758835920930643. eCollection 2020 [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
23. **CAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma**
Messori A, Damuzzo V, Leonardi L, Agnoletto L, Chiumente M, Mengato D.
Clin Lymphoma Myeloma Leuk. 2020 Feb 19:S2152-2650(20)30087-2. doi: 10.1016/j.clml.2020.02.007 [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

- 24. Tisagenlecleucel in non-Hodgkin lymphoma: the restricted mean survival time as a tool for estimating progression-free life expectancy better than the median**
M. Chiumente, D. Mengato, A. Messori
Acta Haematol. 2020 Feb 19:1-2. doi: 10.1159/000505891 [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 25. Tyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regression**
M. Rivano, L. Cancanelli, A. Zovi, C. Addis, D. Mengato, M. Chiumente, A. Messori
J Chemother [PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 26. A model-independent method to determine restricted mean survival time in the analysis of survival curves**
Messori A., Damuzzo V., Agnoletto L., Leonardi L., Chiumente M., Mengato D.
SN Comprehensive Clinical Medicine 2020 2:1 (66-68) [EMBASE and GOOGLE SCHOLAR INDEXED]
- 27. HTA Metro Map: a patient centred model for optimizing the decision-making process**
Chiumente M, Kamal KM, Dauben HP, Riedel R, Gutierrez Ibarluzea I
I GMS Health Innov Technol 2019 15 Dic 02 doi: 10.3205/hta.000132
[PUBMED, GOOGLE SCHOLAR INDEXED]
- 28. Analysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term Survivors.**
Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A.
Front Oncol. 2019 Jun 4;9:453. doi: 10.3389/fonc.2019.00453. eCollection 2019.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 29. Trastuzumab biosimilar in metastatic breast cancer: evaluating equivalence with originator by network meta-analysis**
D. Mengato, M. Chiumente, A. Messori
Int J Clin Pharmacol Ther. 2019 Mar;57(3):160-162. doi: 10.5414/CP203351
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 30. Safety of intravitreal injections: non-inferiority of bevacizumab compared with ranibizumab**
M. Chiumente, V. Damuzzo, L. Agnoletto, L. Leonardi, D. Mengato
Int J Clin Pharmacol Ther. 2019 Jan;57(1):41-42. doi: 10.5414/CP203348.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 31. Optimization of resources by drug management: a multicentred web-administered study on the use of ipilimumab in Italy**
Damuzzo V., Russi A., Chiumente M., Masini C., Rebesco B., Gregis F., Nozza S., Pigozzo J., Chiarion-Sileni V., Palozzo A.C
Journal of Oncology Pharmacy Practice 2018 Jan 1:1078155218755867.
doi:10.1177/1078155218755867
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 32. Ulipristal acetate for pre-operative management of uterine fibroids: modeling outcomes and costs.**
B. Badiani, M. Chiumente, A. Messori
European Journal of Obstetrics & Gynecology and Reproductive Biology. 2018 Mar;222:84-88.
doi: 10.1016/j.ejogrb.2018.01.020. Epub 2018 Feb 3
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 33. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes and consumption of health care resources in more than 5000 women**
Chiumente M, De Rosa M, Messori A, Proli EM.
Clinicoecon Outcomes Res. 2017 Aug 29;9:525-535. doi: 10.2147/CEOR.S139335. eCollection 2017. Erratum in: Clinicoecon Outcomes Res. 2017 Oct 17;9:653.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]

- 34. Promoting the use of Markovian simulation models to study outcomes of thrombectomy after acute ischemic stroke**
S. Trippoli, M. Chiumente, A. Messori
J Cardiovasc Med (Hagerstown). 2017 Oct;18(10):777-779. doi: 10.2459/JCM.0000000000000532.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 35. Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.**
Chiumente M, Messori A.
Ther Adv Musculoskelet Dis. 2017 Oct;9(10):271-273. doi: 10.1177/1759720X17721151. Epub 2017 Aug 23.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 36. Rituximab biosimilar evaluated by network meta-analysis.**
Chiumente M, Mengato D, Messori A.
Haematologica. 2017 Sep 21. pii: haematol.2017.175042. doi: 10.3324/haematol.2017.175042. [Epub ahead of print]
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 37. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.**
Russi A, Damuzzo V, Chiumente M, Pigozzo J, Cesca M, Chiarion-Sileni V, Palozzo AC. J Chemother. 2017 Apr 11:1-7. doi: 10.1080/1120009X.2017.1311444.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 38. Comorbidity, polytherapy and drug interactions in a neurological context: an example of a multidisciplinary approach to promote the rational use of drugs.**
G.Busa, G. Burlina, V.Damuzzo, M. Chiumente, A.C. Palozzo.
J Pharm Pract. 2018 Feb;31(1):58-65. doi: 10.1177/0897190017699138. Epub 2017 Mar 21
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 39. The Life Cycle of Health Technologies. Challenges and Ways Forward.**
Gutiérrez-Ibarluzea I, Chiumente M, Dauben HP.
Front Pharmacol. 2017 Jan 24;8:14. doi: 10.3389/fphar.2017.00014.
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 40. Capacity building in agencies for efficient and effective Health technology assessment**
T. Schuller, D.Mueller, M. Chiumente, I.Gutiérrez-Ibarluzea
Int J Technol Assess Health Care. 2016 Jan;32(4):292-299. DOI:10.1017/S0266462316000490
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 41. Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke.**
Chiumente M, Trippoli S, Messori A.
J Stroke. 2016 Feb 26. doi: 10.5853/jos.2015.01662
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 42. Burden of stroke in Italy: an economic model highlights savings from reduced disability following thrombolysis**
M. Chiumente, M.M. Gianino, D. Minniti, T. Mattei, D. Zimmerman, B. Spass, K. Kamal, A. Muca, E. Luda
Int J Stroke. 2015 Aug;10(6):849-55. doi: 10.1111/ijss.12481. Epub 2015 Apr 8
[PUBMED, EMBASE and GOOGLE SCHOLAR INDEXED]
- 43. Il costo della distribuzione diretta dei farmaci in dieci aziende sanitarie piemontesi**
F. Cattel, M. Chiumente, C. Jommi, A Bianco, G. Valinotti
GIFC 2015;29(3):152-169 | DOI 10.1721/2016.21938
[EMBASE and GOOGLE SCHOLAR INDEXED]
- 44. Economic impact of antifungal treatment in IFD by Candida spp: anidulafungin administration as a cost-effective alternative for critical care patients**

F. Cattel, F. Ancona, M. Chiumente, A. Miliacca, I. Motta, F.G. De Rosa.
Eur J Hosp Pharm doi:10.1136/ejhpharm-2013-000408
[EMBASE and GOOGLE SCHOLAR INDEXED]

45. Esperienza di collaborazione interdisciplinare farmacista di reparto-ematologo per la gestione della terapia antifungina sistemica in un reparto di ematologia.

M. Scaldaferri, E. Sciorsci, M. Canepari, A. Bianco, M. Viglione, E.J. Pennone, E. Cerutti, D. Barilà, A. Chiesa, V. Manescotto, M. Chiumente, M. Ferroni, M. Massaia, S. Stecca, F. Cattel
DOI 10.1704/1031.11254 *Bollettino SIFO (Società italiana di Farmacia Ospedaliera) vol. 57 n 5 2011* [GOOGLE SCHOLAR INDEXED]

Autorizzo il trattamento dei dati personali ai sensi e per gli effetti del decreto legge 196/2003 per le finalità di cui al presente avviso di candidatura.